Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on March 19, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Collegium Pharma to acquire AZSTARYS ADHD drug for $650M cash plus up to $135M in regulatory/commercial milestone payments.
COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Collegium Pharma to acquire AZSTARYS ADHD drug for $650M cash plus up to $135M in regulatory/commercial milestone payments
- Acquisition targets GPC Commave Holding LLC and NewCo from Corium subsidiaries, expanding CNS stimulant portfolio
- Closing expected in Q2 2026, subject to Hart-Scott-Rodino clearance and customary conditions
- Termination fee $24M payable by Collegium if deal fails under specified conditions, indicating deal seriousness
- Strategic move to enhance ADHD treatment offerings with a commercially approved drug, potentially boosting future revenues
Item 7.01 · Regulation FD Disclosure
- Announcement of AZSTARYS® acquisition signals strategic expansion of COLLEGIUM's ADHD portfolio and commercial footprint
- Presentation and press release from March 19, 2026 provide details on acquisition rationale and expected financial impact
- Forward-looking statements highlight risks on closing timing, regulatory approvals, integration, and realization of anticipated benefits
- Key risks include possible delays, failure of transaction, unknown liabilities, litigation, and competitive market challenges
- Investors should monitor subsequent filings for updates on transaction progress, financial forecasts, and potential operational disruptions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings
Get the next COLL 8-K as it lands
Follow COLL for push alerts, or ask the research agent what this filing means.